U.S. markets closed
  • S&P Futures

    4,274.50
    -6.50 (-0.15%)
     
  • Dow Futures

    33,664.00
    -54.00 (-0.16%)
     
  • Nasdaq Futures

    13,554.75
    -23.00 (-0.17%)
     
  • Russell 2000 Futures

    2,013.30
    -3.60 (-0.18%)
     
  • Crude Oil

    91.76
    -0.33 (-0.36%)
     
  • Gold

    1,816.80
    +1.30 (+0.07%)
     
  • Silver

    20.77
    +0.08 (+0.37%)
     
  • EUR/USD

    1.0261
    -0.0065 (-0.63%)
     
  • 10-Yr Bond

    2.8490
    -0.0390 (-1.35%)
     
  • Vix

    19.53
    -0.67 (-3.32%)
     
  • GBP/USD

    1.2130
    -0.0072 (-0.59%)
     
  • USD/JPY

    133.5180
    +0.5190 (+0.39%)
     
  • BTC-USD

    24,326.63
    -148.39 (-0.61%)
     
  • CMC Crypto 200

    574.64
    +3.36 (+0.59%)
     
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • Nikkei 225

    28,546.98
    +727.68 (+2.62%)
     

Inhibikase Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity

  • Oops!
    Something went wrong.
    Please try again later.
·8 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BOSTON and ATLANTA, Nov. 15, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today reported financial results for the third quarter ended September 30, 2021 and highlighted recent developments.

Inhibikase Therapeutics, Inc. Logo (PRNewsfoto/Inhibikase Therapeutics, Inc.)
Inhibikase Therapeutics, Inc. Logo (PRNewsfoto/Inhibikase Therapeutics, Inc.)

Key Business and Clinical Highlights

  • Dosed first patient in the Phase 1b clinical trial of IkT-148009: In October 2021 Inhibikase dosed the first patient in its Phase 1b clinical trial of IkT-148009, a randomized, placebo-controlled trial to evaluate the safety, tolerability, and pharmacokinetics of IkT-148009. The trial will enroll a total of 24 patients with Parkinson's disease and also assess non-motor and motor function, gut motility, and measures of alpha-synuclein aggregate clearance, as exploratory endpoints. The Company expects to complete this study and, with the approval of the U.S. Food and Drug Administration (FDA), advance into a Phase 2a study in 2022.

  • Extended Phase 1 clinical trial of IkT-148009 to higher doses: In October 2021, Inhibikase expanded dosing of IkT-148009 in older and elderly healthy volunteers up to a single 250 mg dose to identify the maximum tolerated dose. This extension was based on the safety and tolerability profile observed in the initial dose cohorts of the Phase 1 study.

  • Submitted interim three-month results from chronic toxicology studies of IkT-148009 to FDA: In October 2021, Inhibikase reported that it had submitted interim three-month results from its ongoing chronic toxicology studies of IkT-148009 in rats and non-human primates to the FDA. Data indicated that the toxicology profile of IkT-148009 improves with extended daily oral dosing and supports evaluation in Parkinson's patients for up to three months.

  • Received grant from U.S. National Institutes of Health to evaluate IkT-148009 for the treatment of Multiple System Atrophy: In September 2021, Inhibikase was awarded a research grant from the U.S. National Institute of Neurological Disease and Stroke (NINDS), an Institute of the National Institutes of Health (NIH), to evaluate the mechanism of the MSA disease process and the therapeutic potential of IkT-148009 in preclinical studies.

"Over the past quarter, we have worked diligently to advance our lead candidate, IkT-148009 in multiple indications. We dosed the first Parkinson's patient in our Phase 1b study as well as submitted interim chronic toxicology data to the FDA to support extended dosing of IkT-148009. We were also pleased to receive a grant from the NIH to evaluate IkT-148009 in a novel preclinical model of MSA, a neurodegenerative disease that may benefit from c-Abl inhibition," commented Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase. "As we look ahead, we expect to file our IND application for IkT-001Pro for the treatment of CML in the first quarter of 2022 as well as anticipate completing our Phase 1b study for Ikt-148009 in 2022."

Third Quarter Financial Results

Net Loss: Net loss for the quarter ended September 30, 2021, was $4.5 million, or $0.18 per share, compared to a net loss of $0.7 million, or $0.08 per share in the third quarter 2020.

R&D Expenses: Research and development expenses were $3.2 million for the quarter ended September 30, 2021 compared to $.1 million in the third quarter 2020. The increase was driven by a $0.3 million increase in grant related research expenditures and a $2.8 million increase in non-grant related research. The non-grant related research was expended primarily in connection with the Company's Phase I Parkinson's disease clinical trial.

SG&A Expenses: Selling, general and administrative expenses for the quarter ended September 30, 2021 were $1.6 million compared to $0.6 million for the third quarter in 2020. The increase was the result of increased non-cash stock compensation expense of $0.1 million, increased director and officer's liability insurance of $0.4 million related to the Company's IPO in December 2020, increased legal fees, board fees, investor relation and consulting fees of $0.3 million relating to operating as a public company registrant since December 2020 and a net increase of $0.2 million for other normal operating expenses.

Cash Position: Cash and cash equivalents were $45 million as of September 30, 2021.

About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain. Inhibikase has completed its planned Phase 1 studies evaluating the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects and has commenced a Phase 1b study in Parkinson's patients. The company has further extended the Phase 1 older and elderly healthy volunteer study to explore the maximum tolerated dose further given the favorable adverse event profile seen to date. Its multi-therapeutic pipeline is pursuing Parkinson's-related disorders of the brain and GI tract, orphan indications related to Parkinson's disease such as Multiple System Atrophy, or MSA, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent Imatinib that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company's RAMP™ medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be applied to other cognitive and motor function diseases of the brain. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.

Social Media Disclaimer
Investors and others should note that we announce material financial information to our investors using our investor relations website, press releases, SEC filings and public conference calls and webcasts. The company intends to also use Twitter, Facebook, LinkedIn and YouTube as a means of disclosing information about the company, its services and other matters and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Inhibikase's current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase's actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Inhibikase's filings with the SEC, including its registration statement on Form S-1, as amended (File No. 333-240036), including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

# # #

Inhibikase Therapeutics, Inc.

Condensed Balance Sheets




September 30,
2021



December 31,
2020




(unaudited)





Assets







Current assets:







Cash


$

44,845,950



$

13,953,513


Grants receivable



217,482





Prepaid research and development



264,381




774,356


Prepaid expenses and other current assets



541,388




54,837


Total assets


$

45,869,201



$

14,782,706


Liabilities and stockholders' equity







Current liabilities:







Accounts payable


$

553,801



$

1,720,680


Accrued expenses and other current liabilities



1,905,010




632,934


Deferred revenue






2,325,741


Notes payable



248,911




42,534


Total



2,707,722




4,721,889


Notes payable, net of current portion






276,461


Total liabilities



2,707,722




4,998,350


Commitments and contingencies (see Note 11)







Stockholders' equity:







Preferred stock, $0.001 par value; 10,000,000 shares authorized at September 30, 2021 and December 31, 2020; 0 shares issued and outstanding at September 30, 2021 and December 31, 2020







Common stock, $0.001 par value; 100,000,000 and 30,000,000 shares authorized; 25,155,198 and 10,050,849 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively.



25,155




10,051


Additional paid-in capital



67,912,392




24,805,929


Accumulated deficit



(24,776,068)




(15,031,624)


Total



43,161,479




9,784,356


Total liabilities and stockholders' equity


$

45,869,201



$

14,782,706


Inhibikase Therapeutics, Inc.

Condensed Statements of Operations

(Unaudited)




Three Months Ended
September 30,



Nine Months Ended
September 30,




2021



2020



2021



2020


Revenue:













Grant revenue


$

328,459



$

37,680



$

3,098,661



$

528,052


Total revenue



328,459




37,680




3,098,661




528,052


Costs and expenses:













Research and development



3,154,553




120,569




7,968,846




666,858


Selling, general and administrative



1,644,946




580,820




4,854,494




1,478,839


Total costs and expenses



4,799,499




701,389




12,823,340




2,145,697


Loss from operations



(4,471,040)




(663,709)




(9,724,679)




(1,617,645)


Interest expense



(157)




(6,890)




(19,765)




(22,263)


Net loss


$

(4,471,197)



$

(670,599)



$

(9,744,444)



$

(1,639,908)


Net loss per share – basic and diluted


$

(0.18)



$

(0.08)



$

(0.61)



$

(0.20)


Weighted-average number of common shares – basic and diluted



25,143,559




8,198,754




15,868,421




8,187,517


Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibikase-therapeutics-reports-third-quarter-2021-financial-results-and-highlights-recent-period-activity-301424662.html

SOURCE Inhibikase Therapeutics, Inc.